- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01225835
Progesterone Serum Levels in Subfertile Female Patients Undergoing in Vitro Fertilisation (IVF) (PREDICT)
Effect of Highly Purified Menotrophin and Recombinant Follicle Stimulating (rFSH, Follitrophin Alpha) in Subfertile Female Patients Undergoing IVF on Progesterone Serum Levels During the Follicular Phase and Their Possible Use as Predictors for the Success Rate of Ongoing Pregnancies
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany
- Fertility Center Berlin
-
Berlin, Germany
- Praxisklinik Sydow am Gendarmenmarkt
-
Dortmund, Germany
- Kinderwunschzentrum Dortmund
-
Dusseldorf, Germany
- Universitätsklinikum Duesseldorf, Frauenklinik
-
Erlangen, Germany
- Praxis für Kinderwunschbehandlung
-
Essen, Germany
- NOVUM Zentrum
-
Saar, Germany
- IVF Zentrum
-
Ulm, Germany
- Endokrinologikum Ulm
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed informed consent
- Subfertile premenopausal female patients eligible for in vitro fertilisation (IVF) treatment
- Aged ≥34 and ≤42 years
- Body mass index of >18 and <28 kg/m^2
- Normal pelvic ultrasound at Screening
- No more than two previous gonadotrophin stimulated cycles of IVF or intracytoplasmic sperm injection (ICSI) in the history of infertility treatment (gonadotrophin stimulated cycles not used for IVF or ICSI do not count; Clomifen cycles are no exclusion criterion)
- At least 3 consecutive ovulatory menstrual cycles of 24-35 days
- No fertility stimulating drugs at all
- Sperm of partner classified as normal according to World Health Organisation (WHO) 2010 criteria
- Clinically normal baseline haematology, clinical chemistry, and urinalysis values
- Negative serum Hepatitis B Surface Antigen (HBsAg), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) antibody tests within the last 6 months prior to Screening
- Endocrine test results within the clinically normal limits at Screening
Exclusion Criteria:
- Presence of any clinically relevant systemic disease (e.g., insulin-dependent diabetes mellitus)
- A history of or current endocrine disease (excluding treated hypothyreosis), including polycystic ovary syndrome (PCOS) and hyperprolactinaemia
- A history of coagulation disorders
- Persistent ovarian cysts (>3 months)
- A history of hypersensitivity to any of the constituents of the study medication or related compounds
- Diagnosed poor (<3 oocytes) responders to prior gonadotrophin stimulated ART-cycle
- History of severe ovarian hyperstimulation syndrome in former gonadotrophin stimulated assisted reproductive technology (ART)-cycle
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Menotrophin
Starting on Day 2 or 3 of the menstrual cycle, 150 IU (up to 300 IU) by subcutaneous injection once per day in the morning for up to 12 days until human chorionic gonadotropin (hCG) criteria are met.
Pituitary down-regulation (cetrorelix), ovulation induction (choriongonadotropin), and luteal phase support (intravaginal progesterone) are administered the same way in both treatment arms.
|
Starting on Day 2 or 3 of the menstrual cycle, 150 IU (up to 300 IU) by subcutaneous injection once per day in the morning for up to 12 days until human chorionic gonadotropin (hCG) criteria are met.
Other Names:
Participants self-inject subcutaneously Cetrorelix in the morning at a daily dose of 0.25 mg/day from Day 5 of gonadotrophin administration on and continue throughout the period of gonadotrophin treatment up to day 12 as a maximum.
The last dose of Cetrorelix is given on the day of ovulation induction.
Other Names:
10,000 IU administered by the Investigator or designated personnel in the evening of the day on which the hCG criterion is met (no later than Day 13).
The criterion for hCG administration is three follicles >+17 mm diameter as shown by pelvic ultrasound examination.
Other Names:
Vaginal gel progesterone is used once daily at a dose of 90 mg for a period of 30 days starting on the day of oocyte retrieval (approximately Day 14).
Other Names:
|
Active Comparator: Follitrophin Alpha
Starting on Day 2 or 3 of the menstrual cycle, 150 IU (up to 300 IU) by subcutaneous injection once per day in the morning for up to 12 days until human chorionic gonadotropin (hCG) criteria are met.
Pituitary down-regulation (cetrorelix), ovulation induction (choriongonadotropin), and luteal phase support (intravaginal progesterone) are administered the same way in both treatment arms.
|
Participants self-inject subcutaneously Cetrorelix in the morning at a daily dose of 0.25 mg/day from Day 5 of gonadotrophin administration on and continue throughout the period of gonadotrophin treatment up to day 12 as a maximum.
The last dose of Cetrorelix is given on the day of ovulation induction.
Other Names:
10,000 IU administered by the Investigator or designated personnel in the evening of the day on which the hCG criterion is met (no later than Day 13).
The criterion for hCG administration is three follicles >+17 mm diameter as shown by pelvic ultrasound examination.
Other Names:
Vaginal gel progesterone is used once daily at a dose of 90 mg for a period of 30 days starting on the day of oocyte retrieval (approximately Day 14).
Other Names:
Starting on Day 2 or 3 of the menstrual cycle, 150 IU (up to 300 IU) by subcutaneous injection once per day in the morning for up to 12 days until human chorionic gonadotropin (hCG) criteria are met.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum Progesterone (P4) Level in the Morning of the Day of Human Chorionic Gonadotrophin (hCG) Administration
Time Frame: approximately day 10
|
Ovulation induction was performed by administration of hCG once three follicles >=17 mm diameter as shown by pelvic ultrasound examination.
This outcome compares the serum progesterone level the morning prior to hCG administration across treatment arm, and also by age stratum (<39 years and >=39 years).
|
approximately day 10
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Receiver Operating Characteristic (ROC) Analysis of Progesterone as Predictor for Ongoing Pregnancy Rate at Day 7 and Day of hCG Administration
Time Frame: Day 7, approximately Day 10 (hCG Administration)
|
The influence of the progesterone level on the ongoing pregnancy rate (in relation to all randomized patients) was determined by means of the receiver operating characteristic (ROC) curve.
Youden's Index (sensitivity + specificity -1) has a range of 0-1, with 0.5 indicating a random effect.
|
Day 7, approximately Day 10 (hCG Administration)
|
Percentage of Participants With Ongoing Pregnancy
Time Frame: approximately 3.5 months from study start (at least 9 weeks after first positive pregnancy test)
|
Ongoing pregnancy is defined as having a positive foetal heart action nine or more weeks after the first positive pregnancy test.
|
approximately 3.5 months from study start (at least 9 weeks after first positive pregnancy test)
|
Number of Follicles at hCG Administration
Time Frame: approximately day 10
|
Number of follicles >=17 mm diameter detected by pelvic ultrasound examination at day of hCG administration.
|
approximately day 10
|
Average Follicle Diameter at hCG Administration
Time Frame: approximately day 10
|
approximately day 10
|
|
Number of Cumulus-oocyte Complexes Retrieved
Time Frame: approximately day 12 after study start
|
Cumulus-oocyte complexes are oocytes with surrounding cumulus cells.
|
approximately day 12 after study start
|
Number of Pronuclear Oocytes
Time Frame: approximately day 13 after study start
|
Pronuclear oocytes are fertilized oocytes.
|
approximately day 13 after study start
|
Number of Participants With Pronuclear Stage Oocytes at Each Quality Grade
Time Frame: approximately day 13
|
The count of participants with different quality grades of pronuclear stage oocytes is offered. Pronuclear stage oocytes are categorized into seven grades (0A, 0B, 1-5) representing different patterns of pronuclear morphology, according to the German Pronuclear Morphology Study Group. 0A is the highest quality oocyte and grade 5 is the lowest quality. Participants can have pronuclear stage oocytes of different grades and therefore are counted more than once. |
approximately day 13
|
Number of Embryos Transferred
Time Frame: approximately day 14
|
Mean number of embryos transferred 2-3 days following oocyte retrieval.
|
approximately day 14
|
Best Quality of an Embryo Transferred
Time Frame: approximately day 14
|
Embryo quality was measured by the following grades:
Grade 1 represents the healthiest embryos and Grade 5 embryos are not viable. |
approximately day 14
|
Number of Frozen Oocytes at Pronuclear Stage
Time Frame: approximately day 14
|
No more than three normally developed embryos were transferred 2-3 days after oocyte retrieval.
Other normally developed embryos were frozen.
|
approximately day 14
|
Endometrial Thickness on Day of hCG Administration
Time Frame: approximately day 10
|
Endometrial thickness was assessed by pelvic ultrasound on the day of hCG administration.
|
approximately day 10
|
Estradiol (E2) Levels on Day of hCG Administration
Time Frame: approximately day 10
|
approximately day 10
|
|
Percentage of Participants With Successful Embryo Transfer
Time Frame: approximately day 18
|
approximately day 18
|
|
Number of Days Stimulated With Gonadotrophins
Time Frame: Day 1 up to Day 12
|
Number of days in which gonadotrophins were administered until hCG criteria were met.
If hCG criteria were not met by day 13, the participant was withdrawn from the study.
|
Day 1 up to Day 12
|
Number of Ampoules of Gonadotrophins Used
Time Frame: Day 1 up to Day 12
|
Number of ampoules of gonadotrophins used with the goal of reaching hCG criteria.
Each ampoule contained 75 IU of either menotrophin or follitrophin alpha.
|
Day 1 up to Day 12
|
Percentage of Participants With Clinical Pregnancy 6 Weeks After the First Positive Pregnancy Test
Time Frame: approximately 2.5 months from start of study, 6 weeks after first positive pregnancy test
|
A pelvic ultrasound scan was performed approximately 6 weeks after the first positive pregnancy test and the presence of an active foetal heart action indicated a clinical pregnancy.
|
approximately 2.5 months from start of study, 6 weeks after first positive pregnancy test
|
Summary of Pregnancy Outcome
Time Frame: up to 10 months
|
Pregnancy outcomes were reported at the optional long-term follow up visit.
|
up to 10 months
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FE999906 CS11
- 2010-019411-37 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infertility
-
Assuta Hospital SystemsMaccabi Healthcare Services, IsraelCompletedInfertility, Female Infertility, Male InfertilityIsrael
-
Radboud University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentCompletedPregnancy | Male Infertility | Female InfertilityNetherlands
-
Sapientiae InstituteTerminated
-
Esraa Gamal AhmedAin Shams Maternity HospitalUnknownUnexplained Female Infertility
-
King's College LondonNot yet recruitingInfertility | Infertility, Female | Infertility Unexplained | Infertility of Tubal Origin
-
Gazi UniversityCompletedMale Infertility | Unexplained Infertility
-
University of WashingtonEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedMale Infertility, AzoospermiaUnited States
-
Wake Forest University Health SciencesWithdrawnUterine Diseases | Endometriosis | Infertility Unexplained | Endometrial Diseases | Infertility; Female, NonimplantationUnited States
-
Pacific Fertility CenterTerminatedPrimary Female Infertility | Secondary Female Infertility
-
Istanbul University - Cerrahpasa (IUC)RecruitingInfertility | Sexual Dysfunction | Infertility, Male | Nurse's Role | Sexuality | Infertility; FemaleTurkey
Clinical Trials on Menotrophin
-
Ferring PharmaceuticalsCompletedInfertilityGermany, United Kingdom
-
Ferring PharmaceuticalsCompleted
-
Ferring PharmaceuticalsCompletedInfertilityKorea, Republic of
-
Zekai Tahir Burak Women's Health Research and Education...CompletedPolycystic Ovary SyndromeTurkey
-
Ferring PharmaceuticalsCompletedInfertilityTurkey, Belgium, Spain, Poland, Czech Republic, Denmark, Sweden